BioSpace News Archive

The Annual General Meeting 2022 of RaySearch Laboratories AB was held only through postal voting in accordance with temporary legislation.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8 at 10:30 am ET.

CENTOGENE today announced that its cloud-based Software as a Service (SaaS) platform for the identification, prioritization, and classification of human genetic variants is now CE-marked under the In Vitro Diagnostics Directive (98/79/EC).

Oncotelic Therapeutics, Inc. today announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2022 financial results on Wednesday, June 8, 2022.

The European Myeloma Network (EMN), and Karyopharm Therapeutics Inc. (Nasdaq: KPTI), today announced the dosing of the first patient in the collaborative EMN29/XPORT-MM-031 study, a randomized, global Phase 3 study evaluating an all-oral regimen of selinexor, Karyopharm’s first-in-class, oral exportin 1 (XPO1) inhibitor.

Aura Biosciences Inc announced that members of its executive team will participate in the following upcoming investor conferences: Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced that it will have a significant presence at SLEEP 2022, taking place June 4 - 8, 2022, in Charlotte, NC.

Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Ghryvelin ™ (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults (AGHD), is now available to healthcare professionals across Europe (subject to reimbursement).